Anacor Pharmaceutical is a biopharmaceutical company developing small-molecule therapeutics from its boron chemistry platform.
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 12, 2013 | Post-IPO Debt | $45M | 1 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 17, 2019
Donut
|
Pre-seed | $1.80M | Apps | — |
Feb 22, 2017
Bitbond
|
Series Unknown | $1.20M | Blockchain | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | — | Post-IPO Debt |